Seasonal Influenza Vaccination of Healthy Working-Age Adults

  title={Seasonal Influenza Vaccination of Healthy Working-Age Adults},
  author={Justin D. Gatwood and Martin I. Meltzer and Mark L. Messonnier and Ismael R. Ortega-Sánchez and Rajesh Balkrishnan and Lisa A. Prosser},
The recent impact of influenza on the working-age population of the US has led to changes in the recommendations for vaccination against seasonal influenza; however, the implications of vaccinating such a population have been debated. A review of cost-effectiveness analyses of vaccinating the working-age population of the US against seasonal influenza was conducted using articles published between January 1990 and January 2010. Studies considered for inclusion were identified using MEDLINE… 

Influenza vaccines in low and middle income countries

Most findings are in line with evidence from high-income countries highlighting that influenza vaccine is likely to provide value for money, but serious methodological limitations do not allow drawing conclusions on cost-effectiveness of influenza vaccination in middle income countries.

Systematic Review of the Cost-Effectiveness of Influenza Immunization Programs: A Canadian Perspective

Overall, universal mass immunization programs were favoured as a cost-effective strategy and quadrivalent vaccines and the inclusion of new technologies and programmatic strategies would provide more insight regarding immunization policy decisions.

Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies

Given the importance of knowing the impact of changes to influenza policy, such complexities need careful treatment using tools such as population-based trial designs, meta-analyses, time-series analyses and transmission dynamic models.

Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review

Although the overall impact of AEFIs on the cost-effectiveness outcomes was found to be low, it is urged that their inclusion in economic evaluations of seasonal influenza vaccines to reflect comprehensive reports for the decision makers and end-users of the vaccination strategies is urged.

Seasonal influenza vaccination coverage among adult populations in the United States, 2005-2011.

Vaccination coverage among adults under age 65 years increased from 2005-2006 through 2010-2011, but substantial racial/ethnic disparities remained in most age groups, and targeted efforts are needed to improve influenza vaccination coverage and reduce disparities.



The effectiveness of vaccination against influenza in healthy, working adults.

Vaccination against influenza has substantial health-related and economic benefits for healthy, working adults and the cost savings were estimated to be $46.85 per person vaccinated.

Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.

Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.

  • K. Nichol
  • Medicine, Political Science
    Archives of internal medicine
  • 2001
Influenza vaccination of healthy working adults on average is cost saving, and these findings support a strategy of routine, annual vaccination for this group, especially when vaccination occurs in efficient and low-cost sites.

Economic evidence of influenza vaccination in children.

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.

Influenza vaccination of healthy working adults younger than 65 years can reduce the rates of ILI, lost workdays, and physician visits during years when the vaccine and circulating viruses are similar, but vaccination may not provide overall economic benefits in most years.

Non-Traditional Settings for Influenza Vaccination of Adults

Using non-traditional settings to deliver routine influenza vaccination to adults is likely to be cost saving for healthy adults aged 50–64 years and relatively cost effective forhealthy adults aged 18–49 years when preferences for averted morbidity are included.

The annual impact of seasonal influenza in the US: measuring disease burden and costs.

Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).

This report updates the 2005 recommendations by the Advisory Committee on Immunization Practices regarding the use of influenza vaccine and antiviral agents and recommends vaccination of children aged 24-59 months and their household contacts and out-of-home caregivers against influenza.

Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

  • A. FioreD. Shay N. Cox
  • Medicine
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports
  • 2009
This report updates the 2008 recommendations by CDC's Advisory Committee on Immunization Practices regarding the use of influenza vaccine for the prevention and control of seasonal influenza and includes a summary of safety data for U.S. licensed influenza vaccines.